Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

BACKGROUND: Off-label use (OLU) of a drug reflects a perceived unmet medical need, which is common in oncology. Cancer drugs are often highly expensive and their reimbursement is a challenge for many healthcare systems. OLU is frequently regulated by reimbursement restrictions. For evidence-based he...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbrand, Amanda Katherina, Schmitt, Andreas Michael, Briel, Matthias, Diem, Stefan, Ewald, Hannah, Hoogkamer, Anouk, Joerger, Markus, Mc Cord, Kimberly Alba, Novak, Urban, Sricharoenchai, Sirintip, Hemkens, Lars G, Kasenda, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890379/
https://www.ncbi.nlm.nih.gov/pubmed/31803503
http://dx.doi.org/10.1136/esmoopen-2019-000596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890379/
https://www.ncbi.nlm.nih.gov/pubmed/31803503
http://dx.doi.org/10.1136/esmoopen-2019-000596

Ejemplares similares